Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 353

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction

Open access
Weis, Sara, Shintani, Satoshi, Weber, Alberto, Kirchmair, Rudolf, Wood, Malcolm, Cravens, Adrianna, McSharry, Heather, Iwakura, Atsushi, Yoon, Young-sup, Himes, Nathan, Burstein, Deborah, Doukas, John, Soll, Richard, Losordo, Douglas, Cheresh, David · 2004 · Journal of Clinical Investigation

Abstract

Ischemia resulting from myocardial infarction (MI) promotes VEGF expression, leading to vascular permeability (VP) and edema, a process that we show here contributes to tissue injury throughout the ventricle.This permeability/edema can be assessed noninvasively by MRI and can be observed at the ultrastructural level as gaps between adjacent endothelial cells.Many of these gaps contain activated platelets adhering to exposed basement membrane, reducing vessel patency.Following MI, genetic or pharmacological blockade of Src preserves endothelial cell barrier function, suppressing VP and infarct volume, providing long-term improvement in cardiac function, fibrosis, and survival.To our surprise, an intravascular injection of VEGF into healthy animals, but not those deficient in Src, induced similar endothelial gaps, VP, platelet plugs, and some myocyte damage.Mechanistically, we show that quiescent blood vessels contain a complex involving Flk, VE-cadherin, and β β-catenin that is transiently disrupted by VEGF injection.Blockade of Src prevents disassociation of this complex with the same kinetics with which it prevents VEGF-mediated VP/edema.These findings define a molecular mechanism to account for the Src requirement in VEGF-mediated permeability and provide a basis for Src inhibition as a therapeutic option for patients with acute MI.Nonstandard abbreviations used: endothelial cell (EC); left anterior descending (LAD); left ventricle (LV); myocardial infarction (MI); Src family kinase (SFK); vascular permeability (VP).Conflict of interest: R. Soll and J. Doukas are employed by TargeGen Inc. and together with D. Cheresh have stock in this company.D. Cheresh is on the Scientific Advisory Board of TargeGen but is not an employee, board member

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci200420702

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 11

  1. 10.1093/cvr/27.9.1555 · doi:10.1093/cvr/27.9.1555
  2. Senger, 1986, Cancer. Res., 46, 5629
  3. Golas, 2003, Cancer Res., 63, 375
  4. 10.1055/s-2001-16100 · doi:10.1055/s-2001-16100
  5. 10.1002/(SICI)1522-2586(199911)10:5<694::AID-JMRI12>3.0.CO;2-J · doi:10.1002/(sici)1522-2586(199911)10:5<694::aid-jmri12>3.0.co;2-j
  6. 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S · doi:10.1002/1097-4644(20010401)81:1<68::aid-jcb1024>3.0.co;2-s
  7. Roberts, 1997, Cancer Res., 57, 765
  8. 10.1016/S0029-7844(98)00505-5 · doi:10.1016/s0029-7844(98)00505-5
  9. 10.1007/s004010051199 · doi:10.1007/s004010051199
  10. Axford-Gatley, 1988, Am. J. Pathol., 131, 452
  11. 10.1007/BF02070166 · doi:10.1007/bf02070166

Cited by

Metadata

Authors
Weis, S., Shintani, S., Weber, A., Kirchmair, R., Wood, M., Cravens, A., McSharry, H., Iwakura, A., Yoon, Y.-S., Himes, N., Burstein, D., Doukas, J., Soll, R., Losordo, D., & Cheresh, D.
Venue
Journal of Clinical Investigation
Published
2004-03-15
Volume
113
Issue
6
Pages
885-894
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2099078722
Cited by
353
References
39
FWCI
8.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.